Fig. 1From: Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenibOverall survival of patients with, compared to patients without, objective response. CI, confidence interval; HR, hazard ratio; OR, objective response; OS, overall survivalBack to article page